Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.
Revenue (Most Recent Fiscal Year) | $26.32B |
Net Income (Most Recent Fiscal Year) | $6.55B |
PE Ratio (Current Year Earnings Estimate) | 11.97 |
PE Ratio (Trailing 12 Months) | 12.45 |
PEG Ratio (Long Term Growth Estimate) | 1.71 |
Price to Sales Ratio (Trailing 12 Months) | 4.43 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 21.67 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 8.91 |
Pre-Tax Margin (Trailing 12 Months) | 34.80% |
Net Margin (Trailing 12 Months) | 30.23% |
Return on Equity (Trailing 12 Months) | 248.47% |
Return on Assets (Trailing 12 Months) | 13.54% |
Current Ratio (Most Recent Fiscal Quarter) | 3.14 |
Quick Ratio (Most Recent Fiscal Quarter) | 2.79 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 11.36 |
Inventory Turnover (Trailing 12 Months) | 1.36 |
Book Value per Share (Most Recent Fiscal Quarter) | $6.86 |
Earnings per Share (Most Recent Fiscal Quarter) | $3.98 |
Earnings per Share (Most Recent Fiscal Year) | $17.69 |
Diluted Earnings per Share (Trailing 12 Months) | $14.71 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Common Shares Outstanding | 534.33M |
Free Float | 531.28M |
Market Capitalization | $115.91B |
Average Volume (Last 20 Days) | 2.19M |
Beta (Past 60 Months) | 0.64 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 0.57% |
Percentage Held By Institutions (Latest 13F Reports) | 75.53% |
Annual Dividend (Based on Last Quarter) | $8.52 |
Dividend Yield (Based on Last Quarter) | 3.93% |